Patents by Inventor Julian Scott Northen

Julian Scott Northen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALT OF A PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE COMPOUND
    Publication number: 20200016158
    Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-tri-methylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.
    Type: Application
    Filed: September 24, 2019
    Publication date: January 16, 2020
    Inventors: Peter Lionel Spargo, Edward James French, Julian Scott Northen, John Mykytiuk
  • Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
    Patent number: 10519175
    Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: December 31, 2019
    Assignee: COMPASS Pathways Limited
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols
  • Salt of a pyrimido[6,1-A]isoquinolin-4-one compound
    Patent number: 10463665
    Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: November 5, 2019
    Assignee: VERONA PHARMA PLC
    Inventors: Peter Lionel Spargo, Edward James French, Julian Scott Northen, John Mykytiuk
  • PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE
    Publication number: 20190119310
    Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 25, 2019
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil
  • SALT OF A PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE COMPOUND
    Publication number: 20180021337
    Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.
    Type: Application
    Filed: February 10, 2016
    Publication date: January 25, 2018
    Inventors: Peter Lionel Spargo, Edward James French, Julian Scott Northen, John Mykytiuk
  • Crystalline forms of a purine derivative
    Patent number: 9573951
    Abstract: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumor activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: February 21, 2017
    Assignee: Cyclacel Limited
    Inventors: Benjamin Mark Skead, Christopher Peter Worrall, Jonathan Charles Christian Atherton, Julian Scott Northen, Philippe Fernandes
  • Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride
    Patent number: 9512065
    Abstract: The invention provides new polymorphs of N—[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: December 6, 2016
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Julian Scott Northen, John Mykytiuk
  • POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE
    Publication number: 20150191421
    Abstract: The invention provides new polymorphs of N—[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 9, 2015
    Inventors: Julian Scott Northen, John Mykytiuk
  • CRYSTALLINE FORMS OF A PURINE DERIVATIVE
    Publication number: 20150148354
    Abstract: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.
    Type: Application
    Filed: October 27, 2014
    Publication date: May 28, 2015
    Inventors: Benjamin Mark SKEAD, Christopher Peter WORRALL, Jonathan Charles Christian ATHERTON, Julian Scott NORTHEN, Philippe FERNANDES
  • Crystalline forms of a purine derivative
    Patent number: 8889861
    Abstract: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: November 18, 2014
    Assignee: Cyclacel Limited
    Inventors: Benjamin Mark Skead, Christopher Peter Worrall, Jonathan Charles Christian Atherton, Julian Scott Northen, Philippe Fernades
  • CRYSTALLINE FORMS OF A PURINE DERIVATIVE
    Publication number: 20130072504
    Abstract: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.
    Type: Application
    Filed: January 24, 2011
    Publication date: March 21, 2013
    Applicant: CYCLACEL LIMITED
    Inventors: Benjamin Mark Skead, Christopher Peter Worrall, Jonathan Charles Christian Atherton, Julian Scott Northen, Philippe Fernades